These include EGFR, MAPK, and Src, well-known to coordinate proliferation and progression in several cancers (Kim et al. 2009; Wagner and Nebreda 2009) Drug screening of targeted therapies revealed several pan-active compounds that show promise as CCA therapeutics. The gene discussed is EGFR; the disease is cholangiocarcinoma.